NCT05107336 - Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions

Healthy Participants

Interventions

DRUG

AZD2693

Participants will receive subcutaneous injection of AZD2693, once per month.

DRUG

Placebo

Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.

Trial Locations (1)

Research Site, Sumida-ku